Some short term negative news overnight that may affect the SP - the US FDA has said they are 'looking into' claims of post treatment malignancies relating to car-t treatments by leading startup, Cabaletta Bio. Shares dipped significantly overnight, but are already recovering. I have personally seen the FDA do this a handful of times, most often to be a signal of activity (i.e. building knowledge and disclosure they are evaluating). Until we see empirical, independant backed up evidence of these claims, they are only that.
It is worth noting however out of the leading Immunotherapy / Car-T players such as Mink, Immunogen, Arovella, CHM, IMU, Allogene, and a handful of others, its likely 2-3 will emerge from this group as the leading players in solving cancer immuno treatments.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)